Impax Laboratories Inc. is now selling a low-cost generic version of Zomig tablets and orally disintegrating Zomig tablets in two strengths. Zomig, or zolmitriptan, is available in tablet and nasal spray form and as tablets that will disintegrate and can be taken without liquid.
Halozyme Therapeutics Inc. has posted results from an early-stage trial that included its drug PEGPH20 as a treatment for pancreatic cancer. Halozyme said PEGPH20 may make tumors more vulnerable to treatment by depleting their defenses and changing their metabolism.
Statins are often suggested to lower cholesterol and prevent heart disease in individuals with obesity, diabetes and metabolic syndrome, which is a combination of medical disorders including excess body fat and/or high levels of blood pressure, blood sugar and/or cholesterol. However...
The U.S. Food and Drug Administration has approved Xofigo to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.
Advances in biotechnology, together with an improved understanding of the underlying biology of disease, have led to the pursuit of more effective targeted therapeutics and the subsequent development of companion diagnostics to identify appropriate patients.
Drug developer Oncothyreon Inc. announced new clinical trial data about an experimental lung cancer treatment that failed to improve the overall survival rate. Oncothyreon said that it identified some patients who appeared to live longer after treatment with Stimuvax.
Prestige Brands Holdings Inc. returned to a profit in its fiscal fourth quarter, benefiting from lower operating expenses and better sales of over-the-counter health care products. The company reported net income of $19.3 million for the three months ending March 31.
A team of researchers have identified a key protein involved in an alternative death pathway known as programmed necrosis. Drugs that mimic the effects of this protein could push cancer cells that are resistant to apoptosis into necrosis instead.
The U.S. Food and Drug Administration has granted Priority Review to Janssen's New Drug Application for simeprevir, an investigational NS3/4A protease inhibitor administered with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C.
Moody's Investors Service has lowered the long-term debt ratings of drug maker Merck & Co. The rating agency put Merck on review for downgrade at the beginning of May following the company's plans to buy back about $7.5 billion worth of its shares over the next 12 months.
Hospira Inc. said that Dr. Sumant Ramachandra was coming back as senior vice president and chief scientific officer, just two months after he had left the company. Ramachandra left the company in March to be president of research and development at Synta Pharmaceuticals Corp.
Developing and maintaining cell lines for therapeutic bioproduction and biomedical research requires efficiency and accuracy. By automating the processes and techniques used in biomolecular research, scientists can achieve standardization, which can improve the speed, quality, and cost of drug discovery.
The Indian government announced the development of a new low-cost vaccine proven effective against a diarrhea-causing virus that is one of the leading causes of childhood deaths across the developing world. The Indian manufacturer of the new rotavirus vaccine pledged to sell it for $1 a dose.
Higher prices for its multiple sclerosis drug Rebif helped German pharmaceutical and high-tech materials company Merck KGaA post a 54 percent rise in first-quarter profit. Merck also saw stronger sales of materials for liquid-crystal displays and raised its profit forecast, saying it would...
Optimer Pharmaceuticals said Monday that it has named Eric Sirota as its chief operating officer. The Jersey City, N.J., company said that Sirota has experience in building pharmaceutical brands and that his appointment fills a significant need at the company. Hank McKinnell, chairman and CEO of of Optimer, said the appointment allows him to focus on the strategic review process.